[144] Roivant Sciences Ltd. SEC Filing

Rhea-AI Filing Summary

Roivant Sciences Ltd. (ROIV) filed a Rule 144 notice disclosing a proposed sale of 611,079 shares of common stock, scheduled approximately 09/23/2025 through Charles Schwab & Co. The filing lists an aggregate market value of $9,129,520.26 and reports 682,881,743 shares outstanding. The shares were acquired as equity compensation on 01/20/2023 for services rendered. The filer also reported three recent sales by Eric Venker totaling 1,200,000 shares between 07/21/2025 and 09/19/2025 with combined gross proceeds shown. The notice includes the standard representation that the seller has no undisclosed material adverse information.

Positive

• Disclosure compliance: The filer provided a complete Rule 144 notice including acquisition details and recent sales, supporting transparency.
• Acquisition origin stated: Shares to be sold were acquired as equity compensation on 01/20/2023, clarifying the holding basis.

Negative

• Substantial insider selling: Recent reported sales by Eric Venker total 1,200,000 shares in the past three months, which is sizable relative to the proposed sale.
• Potential supply pressure: Proposed additional sale of 611,079 shares (~$9.13M) may increase available float near the sale date.

Insights

Securities Analyst

TL;DR: Insider proposes to sell 611k ROIV shares; recent insider sales totaled 1.2M shares, representing notable insider liquidity.

The Rule 144 filing documents a proposed 611,079-share sale valued at about $9.13 million scheduled for 09/23/2025 and confirms the shares were granted as equity compensation on 01/20/2023. The filing also discloses three recent sales by Eric Venker totaling 1,200,000 shares with material gross proceeds reported. From a securities-structure perspective, these disclosures are routine but the magnitude of recent insider disposals is material to investor perception of insider liquidity and potential supply pressure. This filing alone does not provide information on motives, trading plans, or impact on share count beyond reported outstanding shares.

Corporate Governance Expert

TL;DR: The submission is a compliant Rule 144 notice documenting compensation-origin shares and prior insider sales; it is procedural but material in scale.

The notice properly identifies the acquisition source as equity compensation and confirms the seller's representation about undisclosed material information. It also itemizes prior sales by the named insider in the past three months. From a governance standpoint, timely and complete Rule 144 disclosures support market transparency. However, the combination of recently executed sales and a new proposed sale merits attention from stakeholders evaluating insider alignment, though the filing does not state any breach of policies or trading-plan adoption.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Charles Schwab & Co 3000 Schwab Way Westlake TX 76262	611079	9129520.26	682881743	09/23/2025	NASDAQ GS

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/20/2023	Equity Compensation	Issuer			611079	01/20/2023	Services Rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eric Venker 7TH FLOOR, 50 BROADWAY LONDON X0 SW1H 0DB	Common Stock	08/20/2025	100000	1172120.12
Eric Venker 7TH FLOOR, 50 BROADWAY LONDON X0 SW1H 0DB	Common Stock	07/21/2025	100000	1151941.91
Eric Venker 7TH FLOOR, 50 BROADWAY LONDON X0 SW1H 0DB	Common Stock	09/19/2025	1000000	10220470.33

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Roivant Sciences' Form 144 filed for ROIV disclose?

The Form 144 discloses a proposed sale of 611,079 shares of common stock scheduled for 09/23/2025, acquired as equity compensation on 01/20/2023.

How much value is the proposed ROIV sale listed at?

The filing reports an aggregate market value of $9,129,520.26 for the 611,079 shares to be sold.

Who has recently sold ROIV shares according to the filing?

The filing lists three recent sales by Eric Venker: 100,000 shares on 07/21/2025 (gross $1,151,941.91), 100,000 shares on 08/20/2025 (gross $1,172,120.12), and 1,000,000 shares on 09/19/2025 (gross $10,220,470.33).

How many ROIV shares are outstanding per the Form 144?

The Form 144 reports 682,881,743 shares outstanding.

What was the nature of payment when the shares were acquired?

The shares were acquired as equity compensation and the consideration is listed as services rendered.